Poziotinib (NOV120101, HM781-36B) is a drug in development by

Hanmi Pharmaceutical Hanmi Pharmaceutical () is a South Korean pharmaceutical industry, pharmaceutical company that is headquartered in Seoul. History 1973 to 2009 Hanmi was founded in 1973 by Lim Sung-ki, who was a pharmacist. It was originally named Lim, Sung-k ...

(in South Korea), Luye Pharma (China), and

Spectrum Pharmaceuticals Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Boston, MA. Drugs Spectrum develops and markets drugs for treatments in hematology and oncology. In January 2019, Spectrum sold off its entire comme ...

(rest of world) for various cancers. It is built on an anilino- quinazoline scaffold and inhibits the epidermal growth factor receptors EGFR, HER2/neu, and

Her 4 Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ''ERBB4'' gene. Alternatively spliced variants that encode different protein isoforms have been described; however, not all variants have been fully characterized ...

and binds covalently to its targets. It was discovered at Hanmi; in August 2014 Hanmi exclusively licensed rights in China to the Chinese company Luye Pharma and in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum. As of 2016 Spectrum had started a Phase II trial of poziotinib a second-line treatment for breast cancer.

References

{{reflist Experimental cancer drugs